Biomarker may boost ovarian cancer response to chemotherapy

A molecule that helps control gene expression may play a role in controlling chemotherapy resistance among patients with the most common form of ovarian cancer.

A study has identified miR-506, a noncoding micro RNA molecule, as a likely robust clinical marker for epithelial ovarian cancer chemotherapy, and as a potential therapy due to its ability to sensitize cancer cells to chemotherapy. These findings were published in the Journal of the National Cancer Institute (2015; doi:10.1093/jnci/djv108).

Epithelial ovarian cancer accounts for approximately 90% of all ovarian cancers. Ovarian cancer is the leading cause of death from gynecologic cancers in the United States.

"MiR-506 was associated with better response to therapy and longer progression-free and overall survival," said Wei Zhang, PhD, professor of Pathology at The University of Texas MD Anderson Cancer Center in Houston.

Zhang's study, which included data from The Cancer Genome Atlas and other independent clinical populations as well as study of mouse models, observed "statistically significant improved responses" to the chemotherapy drugs cisplatin and olaparib when miR-506 was added to the treatment. Standard treatments include surgery and platinum-based chemotherapy, and the 5-year survival rate for patients with advanced ovarian cancer is 30% to 40%.

Chemoresistance is a major challenge in cancer treatment and this study may provide a means to overcome resistance, said Zhang.

"Our previous study found that miR-506 is a potent inhibitor of a process known as epithelial-to-mesenchymal transition (EMT), which is also associated with chemoresistance," he said. "This study provides further insight into this molecule's role in augmenting chemotherapy responses by directly affecting the DNA repair process used by cancer cells to counter DNA damages caused by chemotherapy."

Prior investigations by Zhang's group observed that miR-506 suppressed cancer cell EMT. The current study showed that miR-506 also regulated RAD51, a protein involved in DNA repair that contributes to chemotherapy resistance when overexpressed.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs